Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Rick Strange who wrote (980)	1/26/2000 7:22:00 PM
From: Gabe Fernandez	Read Replies (2) \| Respond to of 1386

Rick I feel the FDA can be made to change .If HU-211 is as effective in controlling ICP as we were led to believe by the statements at the Congress of Neurological Surgeons meeting in Seattle. Managing ICP is very difficult and we really have no real good alternative to the same in management. Trauma centers,intensenist and Neurosurgeons would place pressure in the approval,especially if the drug proves safe like the Pharmos study in Israel indicated